Improving aqueous solubility and in vitro pharmacokinetic properties of the 3-nitroimidazo[1,2-a]pyridine antileishmanial pharmacophore

2022

Article référencé dans le Web of Science WOS:000845714300001

Paoli-Lombardo R., Primas N., Bourgeade-Delmas Sandra, Hutter S., Sournia-Saquet A., Boudot C., Brenot E., Castera-Ducros C., Corvaisier S., Since M., Malzert-Freon A., Courtioux B., Valentin A., Verhaeghe P., Azas N., Rathelot P., Vanelle P.

Pharmaceuticals, 2022, 15 (8), p. 998 [24 p.]

An antileishmanial structure-activity relationship (SAR) study focused on positions 2 and 8 of the imidazo[1,2-a]pyridine ring was conducted through the synthesis of 22 new derivatives. After being screened on the promatigote and axenic amastigote stages of Leishmania donovani and L. infantum, the best compounds were tested against the intracellular amastigote stage of L. infantum and evaluated regarding their in vitro physicochemical and pharmacokinetic properties, leading to the discovery of a new antileishmanial6-chloro-3-nitro-8-(pyridin-4-yl)-2-[(3,3,3-trifluoropropylsulfonyl)methyl]imidazo[1,2-a]pyridine hit. It displayed low cytotoxicities on both HepG2 and THP1 cell lines (CC50 > 100 mu M) associated with a good activity against the intracellular amastigote stage of L. infantum (EC50 = 3.7 mu M versus 0.4 and 15.9 mu M for miltefosine and fexinidazole, used as antileishmanial drug references). Moreover, in comparison with previously reported derivatives in the studied series, this compound displayed greatly improved aqueous solubility, good mouse microsomal stability (T-1/2 > 40 min) and high gastrointestinal permeability in a PAMPA model, making it an ideal candidate for further in vivo studies on an infectious mouse model.

Sciences fondamentales / Techniques d'analyse et de recherche [020] ; Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]

Fonds IRD [F B010086035]

PAR00025096